Histone H2B Activators
The chemical class of Histone H2B activators comprises a specific group of compounds known as histone deacetylase (HDAC) inhibitors, strategically designed to directly influence the expression of Histone H2B, a fundamental component of chromatin structure. These activators play a pivotal role in the realm of epigenetic regulation, particularly by targeting the acetylation status of histones. Histone H2B, a central player in chromatin dynamics, undergoes post-translational modifications, including acetylation, a process that profoundly impacts gene expression. The HDAC inhibitors identified in this class, including Trichostatin A, Vorinostat, Entinostat, Suberoylanilide Hydroxamic Acid (SAHA), Romidepsin, Panobinostat, MS-275, Scriptaid, Belinostat, CI-994, RGFP966, and TMP195, stand out as potent agents capable of directly activating Histone H2B by inhibiting HDACs.
HDACs, as enzymes, play a crucial role in the deacetylation of histones, leading to chromatin condensation and transcriptional repression. The chemical class of HDAC inhibitors disrupts this deacetylation process, maintaining an open chromatin structure and facilitating increased transcription of Histone H2B. This direct activation of Histone H2B underscores the pivotal role of acetylation in finely regulating its expression, providing a precise and targeted approach to modulate its levels in diverse cellular and molecular contexts. The profound understanding of the delicate balance between histone acetylation and the transcriptional regulation of Histone H2B offers valuable insights into the intricate epigenetic mechanisms that govern chromatin dynamics. In the hands of researchers, these HDAC inhibitors, acting as Histone H2B activators, serve as indispensable tools for studying and dissecting epigenetic modifications and chromatin remodeling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase (HDAC) inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs enhances histone acetylation, leading to increased transcription of Histone H2B. Trichostatin A's role as a direct activator highlights the importance of histone acetylation in regulating Histone H2B expression, providing a molecular tool for modulating its levels in various cellular contexts. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs increases histone acetylation, promoting transcription of Histone H2B. Vorinostat's role as a direct activator underscores the significance of histone acetylation in controlling Histone H2B expression, offering a pharmacological approach to modulate its levels in different cellular and molecular environments. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
Romidepsin, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs enhances histone acetylation, leading to increased transcription of Histone H2B. Romidepsin's role as a direct activator underscores the significance of histone acetylation in regulating Histone H2B expression, providing a therapeutic approach to modulate its levels in different cellular and molecular environments. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Panobinostat, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs increases histone acetylation, promoting transcription of Histone H2B. Panobinostat's role as a direct activator emphasizes the regulatory role of histone acetylation in controlling Histone H2B expression, providing a targeted approach for modulating its levels in diverse cellular contexts. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Belinostat, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs enhances histone acetylation, leading to increased transcription of Histone H2B. Belinostat's role as a direct activator emphasizes the critical role of histone acetylation in regulating Histone H2B expression, offering a pharmaceutical approach to modulate its levels in different cellular and molecular contexts. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $97.00 $525.00 | 1 | |
CI-994, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs increases histone acetylation, promoting transcription of Histone H2B. CI-994's role as a direct activator highlights the significance of histone acetylation in controlling Histone H2B expression, providing a therapeutic avenue for modulating its levels in various cellular and molecular environments. | ||||||
RGFP966 | 1357389-11-7 | sc-507300 | 5 mg | $115.00 | ||
RGFP966, an HDAC inhibitor, directly activates Histone H2B by inhibiting HDACs. Inhibition of HDACs enhances histone acetylation, leading to increased transcription of Histone H2B. RGFP966's role as a direct activator underscores the regulatory role of histone acetylation in controlling Histone H2B expression, providing a targeted approach for modulating its levels in diverse cellular contexts. | ||||||